



Evolut Clinical Guideline 3214 for Tagrisso™ (osimertinib)

Guideline Number: Evolut_CG_3214	<u>Applicable Codes</u>	
<i>"Evolut" refers to Evolut Health LLC and Evolut Specialty Services, Inc. © 2016 - 2025 Evolut. All rights Reserved.</i>		
Original Date: March 2016	Last Revised Date: November 2025	Implementation Date: November 2025

TABLE OF CONTENTS

STATEMENT	2
PURPOSE	2
INDICATIONS	2
NON-SMALL CELL LUNG CANCER (NSCLC)	2
CONTRAINDICATIONS/WARNINGS	3
EXCLUSION CRITERIA	3
CODING AND STANDARDS	4
CODES	4
APPLICABLE LINES OF BUSINESS	4
POLICY HISTORY	4
LEGAL AND COMPLIANCE	4
GUIDELINE APPROVAL	4
Committee	4
DISCLAIMER	5
REFERENCES	5

STATEMENT

Purpose

To define and describe the accepted indications for Tagrisso (osimertinib) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

Evolent is responsible for processing all medication requests from network ordering providers. Medications not authorized by Evolent may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

INDICATIONS

Continuation requests for a not-approvable medication shall be exempt from this Evolent policy provided

- The member has not experienced disease progression on the requested medication AND
- The requested medication was used within the last year without a lapse of more than 30 days of having an active authorization AND
- Additional medication(s) are not being added to the continuation request.

Non-Small Cell Lung Cancer (NSCLC)

- Tagrisso (osimertinib) may be used with or without platinum-based chemotherapy in adult members for the first-line treatment of recurrent or metastatic EGFR positive NSCLC (Exon 19 deletion or Exon 21 L858R point mutation).
- Tagrisso (osimertinib) may be used in adult members as subsequent therapy for EGFR T790M mutation-positive, metastatic NSCLC following progression on Tarceva (erlotinib), Gilotrif (afatinib), Iressa (gefitinib), or Vizimpro (dacomitinib).
- Tagrisso (osimertinib) may be used with or without chemotherapy in adult members as adjuvant therapy in EGFR positive (Exon 19 deletion or Exon 21 L858R point mutation), stage IB-III A NSCLC that has been completely resected. Maximum duration of such adjuvant therapy with Tagrisso (osimertinib) is up to 3 years.
- Tagrisso (osimertinib) may be used in adult members with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations.

CONTRAINDICATIONS/WARNINGS

- None

EXCLUSION CRITERIA

- Disease progression while taking Tagrisso (osimertinib).
- Dosing exceeds single dose limit of 80 mg.
- Member has an uncommon EGFR Exon 20 insertion mutation.
- Lack of documentation for EGFR mutation confirmed by a standard test.
- Treatment exceeds the monthly maximum limit of 30 (80 mg) tablets or 30 (40 mg) tablets.
- Investigational use of Tagrisso (osimertinib) with an off-label indication that is not sufficient in evidence or is not generally accepted by the medical community. Sufficient evidence that is not supported by CMS recognized compendia or acceptable peer reviewed literature is defined as any of the following:
 - Whether the clinical characteristics of the patient and the cancer are adequately represented in the published evidence.
 - Whether the administered chemotherapy/biologic therapy/immune therapy/targeted therapy/other oncologic therapy regimen is adequately represented in the published evidence.
 - Whether the reported study outcomes represent clinically meaningful outcomes experienced by patients. Generally, the definitions of Clinically Meaningful outcomes are those recommended by ASCO, e.g., Hazard Ratio of less than 0.80 and the recommended survival benefit for OS and PFS should be at least 3 months.
 - Whether the experimental design, considering the drugs and conditions under investigation, is appropriate to address the investigative question. (For example, in some clinical studies, it may be unnecessary or not feasible to use randomization, double blind trials, placebos, or crossover).
 - That non-randomized clinical trials with a significant number of subjects may be a basis for supportive clinical evidence for determining accepted uses of drugs.
 - That case reports are generally considered uncontrolled and anecdotal information and do not provide adequate supportive clinical evidence for determining accepted uses of drugs.
 - That abstracts (including meeting abstracts) without the full article from the approved peer-reviewed journals lack supporting clinical evidence for determining accepted uses of drugs.

CODING AND STANDARDS

Codes

- J8999 - osimertinib

Applicable Lines of Business

<input type="checkbox"/>	CHIP (Children’s Health Insurance Program)
<input checked="" type="checkbox"/>	Commercial
<input checked="" type="checkbox"/>	Exchange/Marketplace
<input checked="" type="checkbox"/>	Medicaid
<input type="checkbox"/>	Medicare Advantage

POLICY HISTORY

Date	Summary
November 2025	<ul style="list-style-type: none"> • Converted to new Evolent guideline template • This guideline replaces UM ONC_1287 Tagrisso (osimertinib) • Updated indication section • Updated exclusion criteria • Updated references
November 2024	<ul style="list-style-type: none"> • Added new indication • Updated maximum dosage form quantities in exclusion criteria • Updated references

LEGAL AND COMPLIANCE

Guideline Approval

Committee

Reviewed / Approved by Evolent Specialty Services Clinical Guideline Review Committee

Disclaimer

Evolent Clinical Guidelines do not constitute medical advice. Treating health care professionals are solely responsible for diagnosis, treatment, and medical advice. Evolent uses Clinical Guidelines in accordance with its contractual obligations to provide utilization management. Coverage for services varies for individual members according to the terms of their health care coverage or government program. Individual members' health care coverage may not utilize some Evolent Clinical Guidelines. Evolent clinical guidelines contain guidance that requires prior authorization and service limitations. A list of procedure codes, services or drugs may not be all inclusive and does not imply that a service or drug is a covered or non-covered service or drug. Evolent reserves the right to review and update this Clinical Guideline in its sole discretion. Notice of any changes shall be provided as required by applicable provider agreements and laws or regulations. Members should contact their Plan customer service representative for specific coverage information.

REFERENCES

1. Soria JC, et al; FLAURA Investigators. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. *N Engl J Med*. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137.
2. Lu S, et al; LAURA Trial Investigators. Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. *N Engl J Med*. 2024 Aug 15;391(7):585-597. doi: 10.1056/NEJMoa2402614.
3. Planchard D, et al; FLAURA2 Investigators. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. *N Engl J Med*. 2023 Nov 23;389(21):1935-1948. doi: 10.1056/NEJMoa2306434.
4. Wu YL, et al; ADAURA Investigators. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. *N Engl J Med*. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071.
5. Papadimitrakopoulou VA, et al. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. *Ann Oncol*. 2020 Nov;31(11):1536-1544. doi: 10.1016/j.annonc.2020.08.2100.
6. Tagrisso prescribing information. AstraZeneca Pharmaceuticals LP. Wilmington, DE 2024.
7. Clinical Pharmacology Elsevier Gold Standard 2025.
8. Micromedex® Healthcare Series: Micromedex Drugdex Ann Arbor, Michigan 2025.
9. National Comprehensive Cancer Network. Cancer Guidelines and Drugs and Biologics Compendium 2025.
10. AHFS Drug Information. American Society of Health-Systems Pharmacists or Wolters Kluwer Lexi-Drugs. Bethesda, MD 2025.
11. Ellis LM, et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. *J Clin Oncol*. 2014 Apr 20;32(12):1277-80.
12. Medicare Benefit Policy Manual Chapter 15 Covered Medical and Other Health Services: <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/bp102c15.pdf>.
13. Current and Resolved Drug Shortages and Discontinuations Reported to the FDA: <http://www.accessdata.fda.gov/scripts/drugshortages/default.cfm>.